This clinical trial by Biogen tested the efficacy and safety of anti-LINGO-1 in patients with relapsing remitting multiple sclerosis (RRMS) or with Secondary progressive multiple sclerosis (SPMS) [59]. The gene discussed is LINGO1; the disease is secondary progressive multiple sclerosis.